Monashee Investment Management’s AN2 Therapeutics ANTX Stock Holding History

Monashee Investment Management’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-33,997	Closed	-$697K	–	106
2023 Q4	$697K	Sell	33,997 -65,498	-66%	-$1.1M	0.12%	37
2023 Q3	$1.6M	Sell	99,495 -82,500	-45%	-$934K	0.67%	47
2023 Q2	$1.55M	Sell	181,995 -65,472	-26%	-$471K	0.37%	42
2023 Q1	$2.44M	Sell	247,467 -202,533	-45%	-$2.25M	0.67%	32
2022 Q4	$4.29M	Buy	450,000 +216,670	+93%	+$2.9M	1.85%	17
2022 Q3	$4.05M	Hold	233,330	–	–	1.5%	7
2022 Q2	$1.81M	Sell	233,330 -200,000	-46%	-$2.65M	0.66%	13
2022 Q1	$6.53M	Buy	+433,330	New	+$6.57M	1.89%	2

Other funds holding ANTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Monashee Investment Management's ANTX Position: Q1 2024 in Review

Monashee Investment Management sold out of AN2 Therapeutics (ANTX) in Q1 2024, closing a stake of 33,997 shares — an estimated $697K sold.

Monashee Investment Management first reported a position in ANTX in Q1 2022 and held it in 8 quarters. The position peaked at $6.53M in Q1 2022. 54 funds tracked by Wall St. Rank hold ANTX as of Q1 2024.

Monashee Investment Management reported no remaining AN2 Therapeutics position as of Q1 2024 after selling out during the quarter.
Monashee Investment Management sold 33,997 AN2 Therapeutics shares in Q1 2024, an estimated $697K.
Monashee Investment Management first reported a position in AN2 Therapeutics in Q1 2022 and held it in 8 quarters.
Monashee Investment Management's AN2 Therapeutics position peaked at $6.53M in Q1 2022.
54 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2024.

Based on Monashee Investment Management's 13F filing for Q1 2024, filed 14 May 2024.